Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, CA, USA.
Methods Mol Biol. 2022;2390:461-482. doi: 10.1007/978-1-0716-1787-8_21.
The improvement in the ability of the pharmaceutical industry to predict human pharmacokinetic behavior are attributable to major technological shifts from 1990 to the present day. The opportunity for the application of AI/ML based approaches in the pharmaceutical industry is driven by the abundance of data sets that exist within individual pharmaceutical and biotech companies and the availability, within these environments, of abundant computing power. This chapter seeks to describe opportunities for artificial intelligence to contribute to the assessment and evaluation of the dug metabolism and pharmacokinetic (DMPK) properties of novel compounds across the drug discovery and development continuum. Many initiatives are already underway with respect to the application of AI/ML in predicting pharmacokinetic profiles so the question is not whether AI will influence pharmacokinetic prediction but rather how to best utilize and incorporate this and how to evaluate the value added from these applications. Since our understanding of the underlying biology of the in vitro and in vivo systems with respect to ADME, one of the key challenges to AI-based methods will be the ability to adapt to data sets that change in quality over time.
医药行业预测人体药代动力学行为能力的提高归因于 1990 年至今的重大技术转变。人工智能/机器学习方法在制药行业的应用机会,是由各个制药和生物技术公司内部存在的大量数据集以及这些环境中丰富的计算能力所驱动的。本章旨在描述人工智能在评估和评价新型化合物的药物代谢和药代动力学(DMPK)特性方面的贡献机会,贯穿药物发现和开发的整个过程。目前已经有许多关于人工智能在预测药代动力学特征方面的应用的举措,因此问题不是人工智能是否会影响药代动力学预测,而是如何最好地利用和整合这一点,以及如何评估这些应用的附加值。鉴于我们对 ADME 方面的体外和体内系统的基础生物学的理解,基于人工智能的方法的一个关键挑战将是能够适应随时间变化的数据集。